scholarly article | Q13442814 |
P356 | DOI | 10.1016/J.CLIM.2003.11.002 |
P698 | PubMed publication ID | 15183151 |
P50 | author | Yassine J Daoud | Q80171578 |
P2093 | author name string | C Stephen Foster | |
A Razzaque Ahmed | |||
Elisabetta Miserocchi | |||
William Christen | |||
Erik Letko | |||
P433 | issue | 3 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | cicatricial pemphigoid | Q627291 |
P304 | page(s) | 303-310 | |
P577 | publication date | 2004-06-01 | |
P1433 | published in | Clinical Immunology | Q15752921 |
P1476 | title | A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies | |
P478 | volume | 111 |
Q38980040 | Autoimmune Blistering Diseases in the Elderly: Clinical Presentations and Management |
Q36711702 | Canadian consensus statement on the use of intravenous immunoglobulin therapy in dermatology |
Q38766862 | Chronic Ocular Complications of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: The Role of Systemic Immunomodulatory Therapy |
Q36264883 | Clinical uses of intravenous immunoglobulin. |
Q36794149 | Efficacy of various intravenous immunoglobulin therapy protocols in autoimmune and chronic inflammatory disorders |
Q39608977 | European Guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology |
Q38776260 | European Guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology. |
Q33385332 | Evidence for the use of intravenous immunoglobulins--a review of the literature |
Q37532013 | High-dose intravenous immunoglobulin (IVIG) therapy in autoimmune skin blistering diseases |
Q36958343 | Human immunoglobulins in intraocular inflammation |
Q24250186 | Interventions for mucous membrane pemphigoid and epidermolysis bullosa acquisita |
Q36359703 | Intravenous immunoglobulin in eye involvement |
Q37933423 | Intravenous immunoglobulin in the treatment of autoimmune bullous dermatoses: an update |
Q36757383 | Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. |
Q49833864 | Mucous membrane pemphigoid |
Q46661473 | Mucous membrane pemphigoid with ocular involvement. Part II: therapy |
Q64230980 | Ocular Mucous Membrane Pemphigoid: Current State of Pathophysiology, Diagnostics and Treatment |
Q36168693 | Ocular cicatricial pemphigoid: manifestations and management |
Q37264280 | Ocular mucous membrane pemphigoid: diagnosis and management strategies. |
Q43789787 | Oral cyclophosphamide without corticosteroids to treat mucous membrane pemphigoid |
Q38067153 | Pemphigoid diseases |
Q39096598 | The 2016 Bowman Lecture Conjunctival curses: scarring conjunctivitis 30 years on. |
Q28067526 | The role of intravenous immunoglobulin in treatment of mucous membrane pemphigoid: A review of literature |
Q36986054 | The use of i.v. IG therapy in dermatology |
Q36960643 | Treatment of pyoderma gangrenosum with intravenous immunoglobulin |
Q41359384 | Treatment strategies in mucous membrane pemphigoid |
Q38169809 | Urban legend series: mucous membrane pemphigoid |
Q83154740 | [Indications for intravenous immunoglobulins] |
Q81317771 | [Intravenous immunoglobulins: therapeutic indications] |
Search more.